LipoScience to Release First Quarter 2014 Financial Results

RALEIGH, N.C., April 28, 2014 (GLOBE NEWSWIRE) -- LipoScience, Inc. (Nasdaq:LPDX) today announced that it will release its first quarter 2014 financial results after the market close on Monday, May 12, 2014. An investor conference call will follow on the same day at 4:30 P.M. ET.

The conference call will be hosted by Howard Doran, President and Chief Executive Officer and Lucy Martindale, Executive Vice President and Chief Financial Officer.

To participate in the call, please dial (877) 303-2523 (U.S. and Canada) or (253) 237-1755 (international). A live webcast will be available on the Investor Relations section of the corporate website at

A replay of the conference call will be available beginning May 12, 2014 at 7:30 P.M. ET and ending on May 24, 2014 by dialing (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international), Conference ID Number: 35743577. A replay of the webcast will be available on the corporate website for two weeks.

About LipoScience, Inc.

LipoScience, Inc. (Nasdaq:LPDX) is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. The NMR LipoProfile® test, the Company's first proprietary test, is an FDA-cleared blood test that directly quantifies LDL particles and provides physicians and their patients with actionable information to personalize management of heart disease. To date, more than 11 million NMR LipoProfile tests have been ordered. LipoScience is striving toward the NMR LipoProfile test becoming the preferred choice by physicians for the management of cardiovascular disease.

The Vantera® Clinical Analyzer is the first FDA-cleared platform that utilizes NMR technology. Its ease of use and quick turnaround time helps maximize efficiency and throughput in the clinical laboratory. For further information on LipoScience, please visit and

CONTACT: Media Contact: Tori Hall LipoScience, Inc. (919) 256-1046 Investor Contact: Bob Yedid ICR, Inc. (646) 277-1250

Source:LipoScience, Inc.